We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Non Small Cell Lung Cancer Evaluation According to Pre-determined Drug-targeting Tumor Markers

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01141686
First Posted: June 10, 2010
Last Update Posted: June 10, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Taipei Medical University WanFang Hospital
June 8, 2010
June 10, 2010
June 10, 2010
May 2009
December 2009   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Non Small Cell Lung Cancer Evaluation According to Pre-determined Drug-targeting Tumor Markers
Non Small Cell Lung Cancer Evaluation According to Pre-determined Drug-targeting Tumor Markers
Evaluate chemotherapy related tumor markers on non small cell lung cancer by fluorescent in situ hybridization and immunohistochemistry, targets to be studied include EGFR, c-MET, topoisomerase II, p53, topoisomerase I, thymidylate synthase, ERCC1, tau, c-myc, RRM1, class III tubulin. These targets have been chosen because they are targets for chemotherapeutic agents that are currently used in clinical management of these diseases. In total 50 specimen will be studied, approximately one third have mutations/deletions of the EGFR gene.To attempt to establish a correlation between the pre-selected tumor markers and response to chemotherapy, and thus to be able to create a clinically useful classification that would provide clinical guidance for selection of the most effective chemotherapy for a individual patient, and thus be able to logically design more effective clinical trials for the future.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Retention:   Samples With DNA
Description:
DNA
Non-Probability Sample
lung cancer patient in wanfang hospital
Lung Cancer
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
90
December 2009
December 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with histologically confirmed lung cancer who received standard platinum-containing doublet chemotherapy followed by EGFR tyrosine kinase inhibitors.

Exclusion Criteria:

  • non
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01141686
IRB98021
No
Not Provided
Not Provided
Hsingjin Eugene Liu, MD PhD, Taipei Medical University WanFang Hospital
Taipei Medical University WanFang Hospital
Not Provided
Principal Investigator: Hsin-Gjin Eugene Liu Taipei Medical University WanFang Hospital
Taipei Medical University WanFang Hospital
June 2010